Boston Scientific's Farapulse pulsed field ablation system has redefined the electrophysiology market with the fastest medtech product launch in recent history, gaining clear share leadership against Medtronic Affera and J&J Varipulse. WATCHMAN left atrial appendage closure continues to penetrate atrial fibrillation patient population. Structural heart and EP combine for double-digit growth segment. Operating leverage strong.
Thesis reviewed May 29, 2026
Boston Scientific Corporation is headquartered in United States, which is currently showing elevated risk signals.
πΊπΈUnited States74REDUCEView United States risk detail βπ₯Healthcare28NEUTRAL| Ticker | Company | Score | Gap | Signal Ξ | Action |
|---|---|---|---|---|---|
| ELV | Elevance Health Inc. | 32 | +7% | β3% | NEUTRAL |
| HCA | HCA Healthcare Inc. | 32 | +9% | β3% | EARLY |
| TEVA | Teva Pharmaceutical Industries Ltd. | 32 | +9% | β3% | NEUTRAL |
| TMO | Thermo Fisher Scientific Inc. | 32 | +11% | β3% | EARLY |
| SYK | Stryker Corporation | 32 | +15% | β3% | EARLY |
| CI | The Cigna Group | 32 | +9% | β3% | NEUTRAL |
| DHR | Danaher Corporation | 32 | +11% | β3% | EARLY |
Investors who hold BSX may also have indirect exposure through these country funds.
Farapulse accounts for 40%+ of EP ablation procedures in adopted accounts
Boston Scientific raises FY26 organic growth guidance to 14%+
WATCHMAN FLX Pro launch drives accelerating LAAC adoption
Estimates Β· Yahoo Finance Β· Not audited figures
| Politician | Party | Type | Amount | Trade Date | Return |
|---|---|---|---|---|---|
| Gilbert CisnerosCA | Buy | $1kβ$15k | May 11, 26 | ||
| Gilbert CisnerosCA | Buy | $1kβ$15k | May 19, 26 | ||
| Gilbert CisnerosCA | Buy | $1kβ$15k | May 29, 26 | ||
| Gilbert CisnerosCA | D | Buy | $1kβ$15k | Feb 10, 26 | -32.8% |
| Gilbert CisnerosCA | D | Buy | $1kβ$15k | Jan 30, 26 | -35.4% |
| Markwayne Mullin | Buy | $15kβ$50k | Dec 29, 25 | -45.1% | |
| John Boozman | Sell | $1kβ$15k | Dec 17, 25 | -48.7% | |
| Gilbert CisnerosCA | D | Sell | $1kβ$15k | Dec 24, 25 | -49.5% |
| John Boozman | Buy | $1kβ$15k | Feb 13, 25 | -52.1% |